Biotech · Private company · Union, NJ, US
Prokaryotics, Inc.
Track this companyFree. Adds Prokaryotics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards10
- Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide BiogenesisFiscal year 2026 · $679.6KNIH RePORTER 5R01AI165740-04 · fetched Nov 12, 2026
- Structure-based design of antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase, Mcd4Fiscal year 2026 · $204KNIH RePORTER 5R21AI185171-02 · fetched Nov 12, 2026
- Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibioticsFiscal year 2026 · $977.5KNIH RePORTER 5R44AI165008-03 · fetched Nov 12, 2026
- Structure-based design of antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase, Mcd4Fiscal year 2025 · $170KNIH RePORTER 1R21AI185171-01A1 · fetched Nov 12, 2026
- Development of an active site inhibitor of Fks1 as a broad spectrum antifungal agentFiscal year 2025 · $299.7KNIH RePORTER 1R44AI188848-01A1 · fetched Nov 12, 2026
- Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibioticsFiscal year 2025 · $996.5KNIH RePORTER 4R44AI165008-02 · fetched Nov 12, 2026
- Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide BiogenesisFiscal year 2025 · $679.7KNIH RePORTER 5R01AI165740-03 · fetched Nov 12, 2026
- Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide BiogenesisFiscal year 2024 · $679.3KNIH RePORTER 5R01AI165740-02 · fetched Nov 12, 2026
- Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesisFiscal year 2024 · $295.6KNIH RePORTER 5R42AI179344-02 · fetched Nov 12, 2026
- Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant StaphylococciFiscal year 2024 · $974.6KNIH RePORTER 5R44AI136213-06 · fetched Nov 12, 2026